AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer

NATICK, Mass., Nov. 25, 2024 /PRNewswire/ -- AffyImmune Therapeutics, a clinical-stage biotechnology company committed to developing its novel, first-in-class ICAM-1 targeting chimeric antigen receptor (CAR) T cell therapy for solid tumors, today announced the appointment of Deyaa Adib, M....